#United States #Los Angeles #Securities Law #DJS Law Group #Capricor

Capricor Therapeutics, Inc. Faces Class Action Lawsuit

On August 18, 2025, the DJS Law Group announced an important development for investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR). A class action lawsuit has been filed against the company, alleging significant violations of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), as well as Rule 10b-5.

Background of the Case

The lawsuit pertains to a period from October 9, 2024, to July 10, 2025, during which shareholders claim that Capricor engaged in misleading practices regarding its drug candidate, deramiocel. The company had publicly asserted that progress towards FDA approval was on track, leading potential investors to believe that there were no underlying issues. However, internal communications have revealed that Capricor was aware of negative data arising from its Phase 2 HOPE-2 trial, which contradicted its positive public statements.

This discrepancy has raised questions among investors about the integrity and transparency of the company, prompting many to reevaluate their investment choices and potentially joining the class action.

Importance of the Class Action

Investors who bought shares of CAPR during the specified class period are encouraged to participate in this lawsuit. Being a lead plaintiff is not a requirement to benefit from any possible financial recovery linked to this action. Interested shareholders should act quickly, as the deadline to register and potentially become part of this case is set for September 15, 2025.

The DJS Law Group aims to provide resources and updates to those registered under its monitoring program, ensuring they remain informed throughout the litigation process without any cost obligation. This is significant as it aligns with their broader practice of advocating for investor rights.

What Shareholders Should Do

If you are a shareholder who feels affected by the misleading claims made by Capricor Therapeutics, immediate action is advised. Contacting the DJS Law Group can be your first step in understanding your rights and exploring options for financial recovery. By enrolling as a shareholder who purchased shares during the designated class period, you will gain access to a portfolio monitoring service that will keep you updated on the case's progress.

Why Choose DJS Law Group?

DJS Law Group is known for its specialization in securities class actions and providing robust representation for investors. Their experience and focus on achieving investor returns through strategic litigation make them a reliable ally for those impacted by corporate misconduct.

With a client base that includes some of the largest hedge funds and alternative asset managers worldwide, DJS Law Group understands the complexities of securities law and is committed to protecting the interests of its clients.

Conclusion

The Capricor Therapeutics class action lawsuit represents a critical opportunity for investors who may have suffered losses due to misleading statements made by the company. Staying informed and engaging with legal representation can help secure your rights as an investor. Don’t wait until the deadline; if you believe you’ve been affected, reach out to DJS Law Group for assistance today. You deserve to be informed and supported during this process, and acting swiftly could be key to recovering any potential losses incurred during the stated class period.